Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Mallinckrodt

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Mallinckrodt's Japan sales performance.

Mallinckrodt

Mallinckrodt doses first patient in muscular dystrophy trial

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function. Mallinckrodt has kicked off a phase II trial of its Duchenne muscular dystrophy candidate, a repurposed drug used for years for inflammatory ... Mallinckrodt’s step forward comes shortly

Deal Watch January 2018

Patent settlement, non-exclusive licence. 200. Mallinckrodt/Baxter International. RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant to control bleeding in surgery.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug Amitizia - for $1.2bn. ... Mallinckrodt is paying $18 per share for Sucampo and will also assume the company’s $360m debt under the terms of

Pharma deals continue to slide

Pharma deals continue to slide products. While this may not have been the reason behind GSK’s termination of its rare disease projects, it has not deterred Mallinckrodt from acquiring Infacare, a US company with a ... 469 (upfront 31). Infacare (US). Mallinckrodt (US/GB). Company

Deal Watch August 2016

Deal Watch August 2016 Mallinckrodt (US) Nuclear Imaging business. IBA Molecular (BE). Asset acquisition. Diagnostic imaging products for use in nuclear medicine including molybdenum-99.

1 2 3 4 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics